8-K: bioAffinity Technologies Faces Nasdaq Delisting Warning

bioAffinity Technologies received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, potentially leading to delisting.

Summary

• bioAffinity Technologies, Inc. received a written notice from Nasdaq on July 30, 2026, stating it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• The company's bid price has closed below $1.00 for thirty consecutive business days, from June 16, 2026, to July 29, 2026.
• Due to a prior reverse stock split (1-for-30 on September 19, 2025), bioAffinity Technologies is not eligible for the standard 180-day compliance period.
• The company plans to appeal the determination by submitting a request to Nasdaq on August 6, 2026.
• The appeal will stay any delisting or suspension of the company's securities pending a decision from the Nasdaq Panel.
• There is no guarantee that the company will regain compliance or maintain its listing on Nasdaq.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the immediate threat of delisting and the ineligibility for a standard compliance period.

Negatives

• The company is not in compliance with Nasdaq's minimum bid price requirement, having closed below $1.00 for 30 consecutive business days.
• bioAffinity Technologies is ineligible for the standard 180-day compliance period due to a recent reverse stock split.
• There is significant uncertainty regarding the company's ability to regain compliance and maintain its Nasdaq listing.

Risks

• Potential delisting from The Nasdaq Capital Market if compliance with the minimum bid price requirement is not achieved.
• The company's securities may be suspended from trading pending the outcome of the appeal.
• The appeal process and decision timeline from the Nasdaq Panel are uncertain and could be unfavorable.
• Forward-looking statements regarding the hearing and decision are subject to risks and uncertainties, with actual results potentially differing materially.

Future Outlook

The company intends to appeal Nasdaq's determination and present its plans to regain compliance. However, there is no assurance of success in regaining compliance or maintaining the listing on The Nasdaq Capital Market. The timing of the hearing and the Panel's decision are subject to uncertainty.

Management Comments

• The Company intends to submit an appeal to Nasdaq on August 6, 2026, which will stay the delisting and suspension of the Company's securities pending the decision of the Panel.
• At the hearing, the Company intends to present its views and its plans to regain compliance with the Minimum Bid Price Requirement.

Industry Context

StockSavvy.ai notes that Nasdaq listing rules, particularly the minimum bid price requirement, are common hurdles for smaller companies. Companies often face delisting if their stock price falls below $1.00 for an extended period, and the inability to utilize standard compliance periods after a reverse stock split can exacerbate this challenge.

Stakeholder Impact

• Shareholders face increased risk of reduced liquidity and potential loss of investment value if the company is delisted from Nasdaq.
• The company's ability to access capital markets may be severely hampered if it is delisted.

Next Steps

• Submit an appeal to Nasdaq on August 6, 2026.
• Present views and plans to regain compliance at the Nasdaq Panel hearing.
• Await the decision of the Nasdaq Panel regarding the appeal and continued listing.

Key Dates

Recommendation

Given the immediate threat of delisting and the uncertainty surrounding the appeal, a 'hold' recommendation is appropriate. Investors should await the outcome of the Nasdaq hearing before making further decisions. The company's ability to regain compliance is uncertain, but the appeal process offers a potential path forward.

Keywords

Nasdaq compliance, minimum bid price, delisting warning, reverse stock split, listing standards, appeal, Nasdaq Capital Market, bioAffinity Technologies